Prescription-only vitamin D formulation launched in the UK
23 June 2015 | By Victoria White
Internis Pharmaceuticals has launched a new MHRA-licensed and approved vitamin D (colecalciferol) formulation in the UK - Fultium-D3 Drops...
List view / Grid view
News
Enrolment stops for Phase II TKM-Ebola-Guinea trial
23 June 2015 | By Victoria White
Tekmira has announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed.
NICE publishes updated guidance to help GPs and patients recognise the signs of cancer
23 June 2015 | By Victoria White
NICE has updated and redesigned its guideline to support GPs and other primary care professionals to recognise the signs and symptoms of cancer...
Celsis Innovations meet the needs of growing manufacturing companies
22 June 2015 | By Celsis International
Celsis Advance II™ system helps Home, Beauty and Pharmaceutical product manufacturers enhance quality assurance while reducing manufacturing cycle times and inventory requirements...
First patient study data show that idarucizumab reverses dabigatran within minutes
22 June 2015 | By Victoria White
Results from an interim analysis of a Phase III study demonstrate that idarucizumab immediately reversed the anticoagulant effect of dabigatran...
Results of Phase 3 study of andexanet alfa presented at ISTH 2015
22 June 2015 | By Victoria White
Full results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced...
Pfizer to acquire GSK meningitis vaccines
22 June 2015 | By Victoria White
Pfizer has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for $130 million...
New analysis from Phase 3 trial of Adcetris in Hodgkin’s lymphoma patients presented at ICML 2015
22 June 2015 | By Victoria White
Results from a new sub-analysis of the Phase 3 Aethera clinical trial of Adcetris were presented at the 13th International Conference on Malignant Lymphoma...
Epizyme releases additional data from Phase 1 study of tazemetostat in non-Hodgkin’s lymphoma
22 June 2015 | By Victoria White
Epizyme has reported results from the ongoing Phase 1 trial of tazemetostat in patients with advanced B-cell non-Hodgkin's lymphoma and solid tumours...
EC approves Opdivo for the treatment of advanced melanoma patients
22 June 2015 | By Victoria White
The European Commission has approved Bristol-Myers Squibb’s Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced melanoma in adults...
CPhI China opens as country invests in R&D
22 June 2015 | By
CPhI China, hosted by UBM EMEA and CCCMHPIE, returns to the Shanghai New International Exhibition Centre, SNIEC, China from 24 to 26 June 2015...
Celsis introduces the all new Celsis Accel™ Rapid Microbial Screening System for midrange test volumes
20 June 2015 | By Celsis International
Celsis’ Accel System for Pharma allows products to be quickly released from micro hold, diminishing manufacturing cycle times and reducing inventory and working capital requirements...
CYRAMZA® (ramucirumab) Hepatocellular Carcinoma data published by The Lancet Oncology
19 June 2015 | By Eli Lilly and Company
Encouraging subgroup findings are basis for new phase III trial...
AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments
19 June 2015 | By AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG has announced the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state...
Bristol-Myers Squibb to present data from the Orencia Phase IIIb AVERT and AMPLE trials
19 June 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb has announced results from new post hoc analyses of the Phase 3b AVERT and AMPLE trials, which included early moderate to severe rheumatoid arthritis (RA) patients with active disease and markers of poor prognosis...
